Gilad S. Gordon

2.7k total citations · 1 hit paper
24 papers, 2.1k citations indexed

About

Gilad S. Gordon is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Gilad S. Gordon has authored 24 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 5 papers in Molecular Biology. Recurrent topics in Gilad S. Gordon's work include CAR-T cell therapy research (5 papers), Cutaneous lymphoproliferative disorders research (4 papers) and Mosquito-borne diseases and control (3 papers). Gilad S. Gordon is often cited by papers focused on CAR-T cell therapy research (5 papers), Cutaneous lymphoproliferative disorders research (4 papers) and Mosquito-borne diseases and control (3 papers). Gilad S. Gordon collaborates with scholars based in United States, Singapore and Colombia. Gilad S. Gordon's co-authors include Maiwenn Al, Ben A. van Hout, Frans Rutten, A C Moses, M C Carey, J S Flier, Robert D. Silver, Martin C. Carey, Jeffrey S. Flier and Alan C. Moses and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Gilad S. Gordon

24 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Costs, effects and C/E‐ratios alongside a clinical trial

1994 757 citations Ben A. van Hout, Maiwenn Al et al. Health Economics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gilad S. Gordon United States	15	618	427	388	295	212	24	2.1k
E. Daudén Spain	39	523 0.8×	505 1.2×	387 1.0×	239 0.8×	246 1.2×	267	5.4k
Alexis Ogdie United States	42	610 1.0×	318 0.7×	344 0.9×	330 1.1×	210 1.0×	291	7.6k
Richard B. Warren United Kingdom	49	539 0.9×	792 1.9×	617 1.6×	342 1.2×	207 1.0×	344	8.1k
Rosa Parisi United Kingdom	18	370 0.6×	316 0.7×	257 0.7×	296 1.0×	58 0.3×	56	4.0k
Daniel B. Shin United States	40	967 1.6×	770 1.8×	585 1.5×	494 1.7×	121 0.6×	105	8.7k
Valentina Orlando Italy	26	275 0.4×	173 0.4×	800 2.1×	102 0.3×	289 1.4×	107	2.7k
Steven Hirschfeld United States	23	802 1.3×	145 0.3×	338 0.9×	180 0.6×	74 0.3×	72	2.1k
Sara Rosenbaum United States	19	147 0.2×	203 0.5×	274 0.7×	171 0.6×	96 0.5×	60	1.7k
David L. Cutler United States	31	938 1.5×	144 0.3×	888 2.3×	83 0.3×	168 0.8×	145	3.9k
Alan Rosenberg Canada	30	601 1.0×	240 0.6×	98 0.3×	252 0.9×	74 0.3×	110	3.2k

Countries citing papers authored by Gilad S. Gordon

Since Specialization

Citations

This map shows the geographic impact of Gilad S. Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilad S. Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilad S. Gordon more than expected).

Fields of papers citing papers by Gilad S. Gordon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilad S. Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilad S. Gordon. The network helps show where Gilad S. Gordon may publish in the future.

Co-authorship network of co-authors of Gilad S. Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Gilad S. Gordon. A scholar is included among the top collaborators of Gilad S. Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilad S. Gordon. Gilad S. Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamid, Omid, Melissa L. Johnson, Jason J. Luke, et al.. (2022). Abstract CT187: Phase 1 Trial of RTX-240, allogeneic red blood cells engineered to express 4-1BBL and trans-presented IL-15, in patients (Pts) with advanced solid tumors. Cancer Research. 82(12_Supplement). CT187–CT187. 3 indexed citations

Corr, Bradley R., Jose M. Pacheco, S. Lindsey Davis, et al.. (2021). Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results.. Journal of Clinical Oncology. 39(15_suppl). 3075–3075. 4 indexed citations

Hamid, Omid, Jason J. Luke, Alexander I. Spira, et al.. (2021). Abstract CT141: A phase 1 trial of RTX-240, an allogeneic engineered red blood cell with cell -surface expression of 4-1BBL and trans-presented IL-15, in patients with advanced solid tumors. Cancer Research. 81(13_Supplement). CT141–CT141. 2 indexed citations

Diamond, Jennifer R., Xuedong Liu, Gilad S. Gordon, et al.. (2019). Abstract B007: OKI-179 is a novel, oral, class I specific histone deacetylase inhibitor in phase 1 clinical trials. Molecular Cancer Therapeutics. 18(12_Supplement). B007–B007. 2 indexed citations

Tambyah, Paul Anantharajah, Jolene Oon, Shi-Hsia Hwa, et al.. (2019). An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages. Vaccine. 37(31). 4344–4353. 14 indexed citations

Patel, Manish R., Gerald S. Falchook, K Hamada, et al.. (2019). Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 37(8_suppl). 48–48. 5 indexed citations

Foss, Francine M., Christiane Querfeld, Youn H. Kim, et al.. (2018). Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.. Journal of Clinical Oncology. 36(15_suppl). 2511–2511. 14 indexed citations

Querfeld, Christiane, Francine M. Foss, Lauren Pinter‐Brown, et al.. (2017). Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients. Blood. 130(Suppl_1). 820–820. 25 indexed citations

Rupp, Richard, Gary J. Luckasen, Judith L. Kirstein, et al.. (2015). Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. Vaccine. 33(46). 6351–6359. 49 indexed citations

10.

Sirivichayakul, Chukiat, Helen Oh, Marsha G. Raanan, et al.. (2015). Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. The Journal of Infectious Diseases. 213(10). 1562–1572. 64 indexed citations

11.

Osorio, Jorge E., Iván Darío Vélez, Cynthia A. Thomson, et al.. (2014). Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. The Lancet Infectious Diseases. 14(9). 830–838. 115 indexed citations

12.

Morrow, Phuong K., Rashmi K. Murthy, Joe Ensor, et al.. (2012). An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer. Cancer. 118(17). 4098–4104. 26 indexed citations

13.

Adjei, Alex A., Roger B. Cohen, Razelle Kurzrock, et al.. (2009). Results of a phase I trial of KX2–391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. Journal of Clinical Oncology. 27(15_suppl). 3511–3511. 14 indexed citations

14.

Hout, Ben A. van, Maiwenn Al, Gilad S. Gordon, & Frans Rutten. (1994). Costs, effects and C/E‐ratios alongside a clinical trial. Health Economics. 3(5). 309–319. 757 indexed citations breakdown →

15.

Sloan, Frank A., et al.. (1993). Hospital Drug Formularies and Use of Hospital Services. Medical Care. 31(10). 851–867. 34 indexed citations

16.

Gordon, Gilad S., et al.. (1991). Charges for comprehensive obstetric care at teaching and nonteaching hospitals. A comparison.. PubMed. 155(6). 616–20. 1 indexed citations

17.

Gordon, Gilad S., Daniel R. Ambruso, William A. Robinson, & John H. Githens. (1989). Intranasal administration of deferoxamine to iron overloaded patients. The American Journal of the Medical Sciences. 297(5). 280–284. 6 indexed citations

18.

Gordon, Gilad S., A C Moses, Robert D. Silver, J S Flier, & M C Carey. (1985). Nasal absorption of insulin: enhancement by hydrophobic bile salts.. Proceedings of the National Academy of Sciences. 82(21). 7419–7423. 255 indexed citations

19.

Kasbekar, D. K. & Gilad S. Gordon. (1979). Effects of colchicine and vinblastine on in vitro gastric secretion.. American Journal of Physiology-Endocrinology and Metabolism. 236(5). E550–E550. 15 indexed citations

20.

Aikawa, Jerry K., et al.. (1958). Urinary and Fecal Excretion of Orally Administered Mg28.. Experimental Biology and Medicine. 98(1). 29–31. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact